Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Operating Leases (2020 - 2025)

Adma Biologics (ADMA) has disclosed Operating Leases for 6 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 22.37% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, down 22.37%, and an annual FY2025 reading of $6.6 million, down 22.37% over the prior year.
  • Operating Leases was $6.6 million for Q4 2025 at Adma Biologics, down from $9.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $10.9 million in Q2 2022 and bottomed at $6.6 million in Q4 2025.
  • Average Operating Leases over 5 years is $9.0 million, with a median of $9.3 million recorded in 2025.
  • The sharpest move saw Operating Leases surged 72.18% in 2021, then decreased 22.37% in 2025.
  • Year by year, Operating Leases stood at $7.5 million in 2021, then skyrocketed by 43.44% to $10.7 million in 2022, then dropped by 8.64% to $9.8 million in 2023, then fell by 12.46% to $8.6 million in 2024, then decreased by 22.37% to $6.6 million in 2025.
  • Business Quant data shows Operating Leases for ADMA at $6.6 million in Q4 2025, $9.4 million in Q3 2025, and $9.3 million in Q2 2025.